May 4 -- AstraZeneca today announced the submission of a new drug application to the U.S. FDA seeking approval for a product combining low dose aspirin with esomeprazole magnesium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers in patients at risk.
The details can be read here.
No comments:
Post a Comment